series-a
Stage
2
Investors
About
myNEO Therapeutics leverages its ImmunoEngine platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond.
Explore myNEO Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.